BaiAotai: The company is stepping up preparations for the BAT8006 clinical trial project and is expected to begin enrolling participants this month.

Baiotai stated in the investor relations meeting that the company will strive to obtain approval for the listing of BAT2206 in the second half of this year and the beginning of next year in major markets. The unblinding time of the first III phase wAMD study of BAT5906 is expected to be at the end of the second quarter of 2025, with DME clinical trials underway. The company has plans to conduct registration clinical trials for CNV and CRVO in the preparatory stage. The development of subcutaneous injection of Tuzumab and cooperation in Europe are progressing. The company will expedite the sale of intravenous injection products that have already been approved in Europe. The company is intensively preparing for the BAT8006 clinical project and expects to start enrolling participants this month.